FOLH1 and prostate carcinoma: The versatility of PSMA-targeted therapy is further underlined by its potential for combination with other treatment modalities, such as chemotherapy, radiosensitizers, immunotherapy, and PSMA-targeted nanomedicines, suggesting a multifaceted strategy to combat prostate cancer [6].